Relay Therapeutics Inc (NASDAQ: RLAY) is -43.23% lower on its value in year-to-date trading and has touched a low of $5.60 and a high of $12.14 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RLAY stock was last observed hovering at around $5.95 in the last trading session, with the day’s gains setting it 0.3%.
Currently trading at $6.25, the stock is -0.64% and -8.26% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.12 million and changing 5.04% at the moment leaves the stock -17.11% off its SMA200. RLAY registered -23.12% loss for a year compared to 6-month loss of -3.99%. The firm has a 50-day simple moving average (SMA 50) of $6.8308 and a 200-day simple moving average (SMA200) of $7.5592.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 0.00% gain in the last 1 month and extending the period to 3 months gives it a -8.09%, and is 9.46% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.10% over the week and 6.18% over the month.
Relay Therapeutics Inc (RLAY) has around 323 employees, a market worth around $1.02B and $35.21M in sales. Profit margin for the company is -916.89%. Distance from 52-week low is 11.61% and -48.52% from its 52-week high. The company has generated returns on investments over the last 12 months (-44.37%).
The EPS is expected to shrink by -2.18% this year
257.0 institutions hold shares in Relay Therapeutics Inc (RLAY), with institutional investors hold 81.66% of the company’s shares. The shares outstanding are 127.46M, and float is at 120.68M with Short Float at 9.82%. Institutions hold 80.21% of the Float.
The top institutional shareholder in the company is SB INVESTMENT ADVISERS (UK) LTD with over 27.9 million shares valued at $181.94 million. The investor’s holdings represent 21.0093 of the RLAY Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 11.7 million shares valued at $76.32 million to account for 8.8125 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 10.54 million shares representing 7.9375 and valued at over $68.74 million, while CASDIN CAPITAL, LLC holds 6.3608 of the shares totaling 8.45 million with a market value of $55.08 million.
Relay Therapeutics Inc (RLAY) Insider Activity
The most recent transaction is an insider sale by Rahmer Peter, the company’s. SEC filings show that Rahmer Peter sold 1,621 shares of the company’s common stock on Oct 28 ’24 at a price of $6.06 per share for a total of $9823.0. Following the sale, the insider now owns 0.39 million shares.
Relay Therapeutics Inc disclosed in a document filed with the SEC on Oct 28 ’24 that Catinazzo Thomas (Chief Financial Officer) sold a total of 6,802 shares of the company’s common stock. The trade occurred on Oct 28 ’24 and was made at $6.06 per share for $41220.0. Following the transaction, the insider now directly holds 0.31 million shares of the RLAY stock.
Still, SEC filings show that on Oct 29 ’24, Catinazzo Thomas (Chief Financial Officer) disposed off 2,300 shares at an average price of $5.95 for $13685.0. The insider now directly holds 304,091 shares of Relay Therapeutics Inc (RLAY).
